

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)



(10) International Publication Number
WO 2021/260510 A1

(51) International Patent Classification:

C07K 14/045 (2006.01) C07K 14/005 (2006.01)
A61K 39/12 (2006.01)

(21) International Application Number:

PCT/IB2021/055396

(22) International Filing Date:

18 June 2021 (18.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/041,945 21 June 2020 (21.06.2020) US
63/208,457 08 June 2021 (08.06.2021) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **CHI, Xiaoyuan Sherry**; c/o Pfizer Inc., 401
N. Middletown Road, Pearl River, New York 10965 (US).
DORMITZER, Philip Ralph; c/o Pfizer Inc., 401 N. Mid-
dletown Road, Pearl River, New York 10965 (US). **LIU,**
Yuhang; c/o Pfizer Inc., 445 Eastern Point Road, Build-
ing 98, Groton, Connecticut 06340 (US). **NICKI, Jennifer**
Anne; c/o Pfizer Inc., 445 Eastern Point Road, Building 98,
Groton, Connecticut 06340 (US). **YAO, Xiaojie**; c/o Pfiz-

er Inc., 445 Eastern Point Road, Building 98, Groton, Con-
necticut 06340 (US). **CHE, Ye**; c/o Pfizer Inc., 445 Eastern
Point Road, Building 98, Groton, Connecticut 06340 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 235 East
42nd Street, MS 235/9/86, New York, New York 10017
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE

FIG. 3A





FIG. 3B



(57) Abstract: The present invention relates to polypeptides and cy-
tomegalovirus (CMV) antigens that include at least two introduced amino
acid mutations relative to the amino acid sequence of the wild-type HCMV
glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a
conformation alternative to the gB postfusion conformation. Also disclosed
are compositions including the polypeptides and uses thereof.

WO 2021/260510 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*